Researchers at the University of Oxford, UK, have developed a groundbreaking AI model to enhance drug discovery by predicting how new compounds interact with specific proteins. This initiative, known as OpenBind, aims to provide extensive experimental data on potential medications, significantly accelerating the development of new therapies.

• 01The OpenBind consortium has released detailed images of 699 compounds binding to the EV-A71 protein, with binding strength measurements for 601 of them.
• 02OpenBind is the first program focused on creating databases for large-scale drug development, involving collaboration with institutions like Columbia University and Sloan Kettering Cancer Center.
• 03The AI model aims to generate new experimental data to improve predictions about drug interactions, moving beyond existing pattern recognition.
• 04Frank von Delft, a structural biology professor at Oxford, emphasized the consortium's collaboration as crucial for rapid advancements in drug discovery.
• 05The data and AI model from OpenBind are available to researchers worldwide, promoting further analysis and development of new therapeutic models.

El avance en el descubrimiento de medicamentos podría resultar en tratamientos más efectivos y accesibles para diversas enfermedades, beneficiando a pacientes y sistemas de salud.